ReviewCarcinogenesis2012
microRNA involvement in human cancer.
Review in Carcinogenesis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 329 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
329 citing papers in PubMed, 2 syntheses or guidelines pooled it, 568 citations in OpenAlex.
- Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Association of the Expression Level of miR-16 with Prognosis of Solid Cancer Patients: A Meta-Analysis and Bioinformatic Analysis.Disease markers · 2020Pooled it
- Multi-Omics Integration Identifies Ferroptosis-Related miRNA-mRNA Networks and Independent Prognostic miRNAs in Triple-Negative Breast Cancer.Journal of clinical practice and research · 2026Article
- CRISPR/Cas9-mediated miR-21 editing in high-grade urothelial carcinoma cells and its biological effects.Molecular biology reports · 2026Article
- Review
- Targeting the miR-325-3p/GSTP1 axis overcomes paclitaxel resistance in triple-negative breast cancer by inducing ferroptosis.Genes & genomics · 2025Article
- The interactions of Fusobacterium nucleatum and Porphyromonas gingivalis with microRNAs: contributions to oral squamous cell carcinoma.Molecular biology reports · 2025Article
- BIM-Ken: Identifying Disease-Related miRNA Biomarkers Based on Knowledge-Enhanced Bio-Network.Genes · 2025Article
- Circulating miRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis.The journal of liquid biopsy · 2025Review
- Role of noncoding RNA as a pacemaker in cancer stem cell regulation: a review article.Journal of the Egyptian National Cancer Institute · 2025Review
- MicroRNA Gets a Mighty Award.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Evaluation of Salivary Carcinogenic microR-21 and miR-125a Expression Associated with Alcohol Consumption and Smoking.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- MicroRNAs Expression Profile in MN1-Altered Astroblastoma.Biomedicines · 2025Article
- MiR-133a-5p Facilitates Cuproptosis in Hepatocellular Carcinoma Through Targeting of ATP7B.Journal of inflammation research · 2025Article
- Review
- miRVim: Three-dimensional miRNA Structure Database.MicroRNA (Shariqah, United Arab Emirates) · 2025Article
- Retracted article: Knockdown of long non-coding RNA AGAP2-AS1 suppresses the proliferation and metastasis of glioma by targeting microRNA-497-5p.Bioengineered · 2024Article
- Impacts ofCurrent issues in molecular biology · 2024Article
- MicroRNA‑1224 inhibits cell proliferation by downregulating CBX3 expression in chordoma.Oncology letters · 2024Article
- Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma.Molecular therapy. Oncology · 2024Review
269 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2026-02-11Concerns/Issues about Referencing/Attributions · Retract and Replace ·
- Retracted
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
When, ∼20 years ago, investigators first determined that components of the genome considered nonfunctional had, in fact, gene regulatory capacity, they probably had no idea of their potential in controlling cell fate and were forced to revise and somehow reorganize their view of the molecular biology. Indeed, it is currently well documented how a class of small non-coding RNAs, microRNAs, are conserved among the species, expressed in different tissues and cell types and involved in almost every biological process, including cell cycle, growth, apoptosis, differentiation and stress response, exerting a finely tuned regulation of gene expression by targeting multiple molecules. As a consequence of the widespread range of processes they are able to influence, it is not surprising that miRNA deregulation is a hallmark of several pathological conditions, including cancer. Indeed, the aberrant expression of these tiny molecules in human tumors is not just a casual association, but they can exert a causal role, as oncogenes or tumor suppressors, in different steps of the tumorigenic process, from initiation and development to progression toward the acquisition of a metastatic phenotype. An increasing body of evidence has indeed proved the importance of miRNAs in cancer, suggesting their possible use as diagnostic, prognostic and predictive biomarkers and leading to exploit miRNA-based anticancer therapies, either alone or in combination with current targeted therapies, with the goal to improve disease response and increase cure rates. Here, we review our current knowledge about miRNA involvement in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.